摘要
目的探讨沙库巴曲缬沙坦钠片应用于扩张型心肌病治疗中的安全性及对血流动力学指标改善和心功能指标产生的影响。方法回顾性选取2020年1—12月该院收治的60例扩张型心肌病患者的临床资料,按照治疗方式的不同将其划分为研究组(n=30,在抗心衰常规药物治疗的基础加用沙库巴曲缬沙坦钠片进行治疗)和常规组(n=30,在抗心衰常规药物治疗的基础上加用培哚普利叔丁胺片进行治疗)。观察评价治疗后两组患者的心功能指标包括:舒张早期/晚期血流峰值速度比值(E/A)水平、左室舒张末期内径(LVEDD)、LVEF左室射血分数、左室收缩末期内径(LVESD)和不良反应发生情况。结果治疗后,研究组E/A比值为(1.29±0.19)、常规组为(1.18±0.13),研究组LVEF水平为(34.66±3.13)%,常规组(34.97±3.20)%,较治疗前均明显提高,差异有统计学意义(t=2.617、4.431,P<0.05);治疗后的研究组LVEDD水平为(52.65±4.02)mm,参照组为(56.68±4.36)mm,研究组LVESD水平为(52.65±4.02)mm,参照组为(62.79±5.12)mm,明显低于治疗前,差异有统计学意义(t=3.722、3.021,P<0.05)。常规组药品不良反应发生率为10.00%,研究组药品不良反应发生率为3.33%,两组不良反应发生率比较,差异无统计学意义(χ^(2)=0.268,P>0.05)。结论在扩张型心肌病的临床治疗中应用沙库巴曲缬沙坦钠片疗效较为理想,对患者的血流动力学指标改善效果显著,患者心功能状况得到良好的提升,具有较高的临床应用价值。
Objective To investigate the safety of sacubitril-valsartan sodium tablets in the treatment of dilated cardiomyopathy and its effect on the improvement of hemodynamic indexes and cardiac function indexes.Methods The clinical data of 60 patients with dilated cardiomyopathy admitted to the hospital from January to December 2020 were retrospectively selected.Acording to the different treatment methods,they were divided into study groups(n=30,on the basis of routine drug treatment of anti heart failure),it was treated with sacubatrovalsartan sodium tablets and the conventional group(n=30,on the basis of conventional anti-heart failure drug treatment,perindopril tert-butylamine tablets were added for treatment).Observation and evaluation of cardiac function indicators in the two groups after treatment included:early/late peak blood flow velocity ratio(E/A)level,left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD)and occurrence of adverse reactions.Results After treatment,the E/A ratio of the study group was(1.29±0.19),that of the conventional group was(1.18±0.13),the LVEF level of the study group was(34.66±3.13)%,and that of the conventional group was(34.97±3.20)%,which were higher than those before treatment,the difference was statistically significant(t=2.617,4.431,P<0.05).After treatment,the LVEDD level in the study group was(52.65±4.02)mm,the conventional group was(56.68±4.36)mm,and the LVESD level in the study group was(52.65±4.02)mm,the conventional group was(62.79±5.12)mm,significantly lower than before treatment,and the difference was statistically significant(t=3.722,3.021,P<0.05).The incidence of adverse drug reactions in the conventional group was 10.00%,and the incidence of adverse drug reactions in the study group was 3.33%.There was no significant difference in the incidence of adverse drug reactions between the two groups(χ^(2)=0.268,P>0.05).Conclusion The application of sacubitril and valsartan sodium tablets in t
作者
汪婷
韩文庄
WANG Ting;HAN Wenzhuang(Department of Cardiovascular Medicine,Zoucheng People's Hospital,Jining,Shandong Province,273500 China)
出处
《中外医疗》
2022年第10期66-69,共4页
China & Foreign Medical Treatment
关键词
扩张型心肌病
沙库巴曲缬沙坦钠片
心功能
Dilated cardiomyopathy
Sacubitril-valsartan sodium tablets
Cardiac function
